In addition to regenerating damaged peripheral nerves, MicroCures is also pursuing siFi2 as a potential therapeutic option for spinal cord regeneration following injury.
Spinal cord injury research has shown that several inhibitory activities prevent healing and regeneration once the nerve has been damaged. These include the formation of a glial scar at the site of injury, which inhibits axon regeneration. Additionally, FL2 and Rho-associated kinase (ROCK), which are natural inhibitors or axon regeneration, become abhorrently overexpressed following injury due to the mistaken belief that axons are diseased.
Preclinical research suggests that siFi2 may help overcome these natural inhibitors and trigger successful axon regeneration and reattachment at the site of injury. In preclinical studies of spinal cord injury in rats, MicroCures has demonstrated that treatment with siFi2 allowed axon growth to occur through the injury’s inhibitory barriers. Researchers did not witness similar axon growth among control animals.
Functional Improvement in Rats
MicroCures has also demonstrated functional improvements in rats with spinal cord injury following treatment with siFi2. This was evidenced by significantly improved hind limb locomotor function in siFi2-treated animals as compared to control subjects at Day 5 (p < 0.05) and Day 7 (p < 0.01).
This video shows the progression of functional improvement for siFi2-treated animals as compared to control animals over a 15-day period.